,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,100 Technology Center Drive,Suite 300,Stoughton,MA,02072,United States,781 713 3699,781 828 4697,https://www.collegiumpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",207,"{'maxAge': 1, 'name': 'Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.', 'age': 58, 'title': 'Co-Founder & Chairman', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 110000, 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,3,2,3,1693526400,1672444800,86400,2,23.19,23.22,22.5,23.27,23.19,23.22,22.5,23.27,0.0,0.832987,7.7303753,691509,691509,304824,312250,312250,22.65,22.69,800,800,805483840,15.4,30.22,1.5001208,22.9676,23.922,0.0,0.0,USD,1242365696,-0.02079,31140123,34734100,7404250,5937207,1690761600,1693440000,0.2132,0.0083,1.16119,20.04,0.258,5.784,3.915975,1672444800,1703980800,1688083200,-11161000,-0.32,2.93,36.98,2.314,5.409,NMS,EQUITY,COLL,COLL,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",1431005400,America/New_York,EDT,-14400000,22.65,37.0,30.0,34.0,34.5,1.8,buy,4,325470016,9.37,229700000,762353024,1.133,1.235,536945984,379.648,15.725,0.03655,-0.05603,345743000,216108496,236487008,0.097,0.77529997,0.42779,0.13393,USD,
1,100 Technology Center Drive,Suite 300,Stoughton,MA,02072,United States,781 713 3699,781 828 4697,https://www.collegiumpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",207,"{'maxAge': 1, 'name': 'Mr. Joseph J. Ciaffoni', 'age': 51, 'title': 'Pres, CEO & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1685780, 'exercisedValue': 516498, 'unexercisedValue': 156150}",9,4,3,2,3,1693526400,1672444800,86400,2,23.19,23.22,22.5,23.27,23.19,23.22,22.5,23.27,0.0,0.832987,7.7303753,691509,691509,304824,312250,312250,22.65,22.69,800,800,805483840,15.4,30.22,1.5001208,22.9676,23.922,0.0,0.0,USD,1242365696,-0.02079,31140123,34734100,7404250,5937207,1690761600,1693440000,0.2132,0.0083,1.16119,20.04,0.258,5.784,3.915975,1672444800,1703980800,1688083200,-11161000,-0.32,2.93,36.98,2.314,5.409,NMS,EQUITY,COLL,COLL,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",1431005400,America/New_York,EDT,-14400000,22.65,37.0,30.0,34.0,34.5,1.8,buy,4,325470016,9.37,229700000,762353024,1.133,1.235,536945984,379.648,15.725,0.03655,-0.05603,345743000,216108496,236487008,0.097,0.77529997,0.42779,0.13393,USD,
2,100 Technology Center Drive,Suite 300,Stoughton,MA,02072,United States,781 713 3699,781 828 4697,https://www.collegiumpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",207,"{'maxAge': 1, 'name': 'Ms. Colleen  Tupper', 'age': 46, 'title': 'Exec. VP & CFO', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 848289, 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,3,2,3,1693526400,1672444800,86400,2,23.19,23.22,22.5,23.27,23.19,23.22,22.5,23.27,0.0,0.832987,7.7303753,691509,691509,304824,312250,312250,22.65,22.69,800,800,805483840,15.4,30.22,1.5001208,22.9676,23.922,0.0,0.0,USD,1242365696,-0.02079,31140123,34734100,7404250,5937207,1690761600,1693440000,0.2132,0.0083,1.16119,20.04,0.258,5.784,3.915975,1672444800,1703980800,1688083200,-11161000,-0.32,2.93,36.98,2.314,5.409,NMS,EQUITY,COLL,COLL,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",1431005400,America/New_York,EDT,-14400000,22.65,37.0,30.0,34.0,34.5,1.8,buy,4,325470016,9.37,229700000,762353024,1.133,1.235,536945984,379.648,15.725,0.03655,-0.05603,345743000,216108496,236487008,0.097,0.77529997,0.42779,0.13393,USD,
3,100 Technology Center Drive,Suite 300,Stoughton,MA,02072,United States,781 713 3699,781 828 4697,https://www.collegiumpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",207,"{'maxAge': 1, 'name': 'Ms. Shirley R. Kuhlmann', 'age': 38, 'title': 'Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec.', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 842898, 'exercisedValue': 0, 'unexercisedValue': 210365}",9,4,3,2,3,1693526400,1672444800,86400,2,23.19,23.22,22.5,23.27,23.19,23.22,22.5,23.27,0.0,0.832987,7.7303753,691509,691509,304824,312250,312250,22.65,22.69,800,800,805483840,15.4,30.22,1.5001208,22.9676,23.922,0.0,0.0,USD,1242365696,-0.02079,31140123,34734100,7404250,5937207,1690761600,1693440000,0.2132,0.0083,1.16119,20.04,0.258,5.784,3.915975,1672444800,1703980800,1688083200,-11161000,-0.32,2.93,36.98,2.314,5.409,NMS,EQUITY,COLL,COLL,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",1431005400,America/New_York,EDT,-14400000,22.65,37.0,30.0,34.0,34.5,1.8,buy,4,325470016,9.37,229700000,762353024,1.133,1.235,536945984,379.648,15.725,0.03655,-0.05603,345743000,216108496,236487008,0.097,0.77529997,0.42779,0.13393,USD,
4,100 Technology Center Drive,Suite 300,Stoughton,MA,02072,United States,781 713 3699,781 828 4697,https://www.collegiumpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",207,"{'maxAge': 1, 'name': 'Mr. Scott  Dreyer', 'age': 50, 'title': 'Exec. VP & Chief Commercial Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 746577, 'exercisedValue': 0, 'unexercisedValue': 143971}",9,4,3,2,3,1693526400,1672444800,86400,2,23.19,23.22,22.5,23.27,23.19,23.22,22.5,23.27,0.0,0.832987,7.7303753,691509,691509,304824,312250,312250,22.65,22.69,800,800,805483840,15.4,30.22,1.5001208,22.9676,23.922,0.0,0.0,USD,1242365696,-0.02079,31140123,34734100,7404250,5937207,1690761600,1693440000,0.2132,0.0083,1.16119,20.04,0.258,5.784,3.915975,1672444800,1703980800,1688083200,-11161000,-0.32,2.93,36.98,2.314,5.409,NMS,EQUITY,COLL,COLL,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",1431005400,America/New_York,EDT,-14400000,22.65,37.0,30.0,34.0,34.5,1.8,buy,4,325470016,9.37,229700000,762353024,1.133,1.235,536945984,379.648,15.725,0.03655,-0.05603,345743000,216108496,236487008,0.097,0.77529997,0.42779,0.13393,USD,
5,100 Technology Center Drive,Suite 300,Stoughton,MA,02072,United States,781 713 3699,781 828 4697,https://www.collegiumpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",207,"{'maxAge': 1, 'name': 'Dr. Thomas B. Smith FAAFP, M.D.', 'age': 61, 'title': 'Exec. VP & Chief Medical Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 692915, 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,3,2,3,1693526400,1672444800,86400,2,23.19,23.22,22.5,23.27,23.19,23.22,22.5,23.27,0.0,0.832987,7.7303753,691509,691509,304824,312250,312250,22.65,22.69,800,800,805483840,15.4,30.22,1.5001208,22.9676,23.922,0.0,0.0,USD,1242365696,-0.02079,31140123,34734100,7404250,5937207,1690761600,1693440000,0.2132,0.0083,1.16119,20.04,0.258,5.784,3.915975,1672444800,1703980800,1688083200,-11161000,-0.32,2.93,36.98,2.314,5.409,NMS,EQUITY,COLL,COLL,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",1431005400,America/New_York,EDT,-14400000,22.65,37.0,30.0,34.0,34.5,1.8,buy,4,325470016,9.37,229700000,762353024,1.133,1.235,536945984,379.648,15.725,0.03655,-0.05603,345743000,216108496,236487008,0.097,0.77529997,0.42779,0.13393,USD,
6,100 Technology Center Drive,Suite 300,Stoughton,MA,02072,United States,781 713 3699,781 828 4697,https://www.collegiumpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",207,"{'maxAge': 1, 'name': 'Dr. Christopher Shayne James M.D.', 'title': 'VP of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,3,2,3,1693526400,1672444800,86400,2,23.19,23.22,22.5,23.27,23.19,23.22,22.5,23.27,0.0,0.832987,7.7303753,691509,691509,304824,312250,312250,22.65,22.69,800,800,805483840,15.4,30.22,1.5001208,22.9676,23.922,0.0,0.0,USD,1242365696,-0.02079,31140123,34734100,7404250,5937207,1690761600,1693440000,0.2132,0.0083,1.16119,20.04,0.258,5.784,3.915975,1672444800,1703980800,1688083200,-11161000,-0.32,2.93,36.98,2.314,5.409,NMS,EQUITY,COLL,COLL,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",1431005400,America/New_York,EDT,-14400000,22.65,37.0,30.0,34.0,34.5,1.8,buy,4,325470016,9.37,229700000,762353024,1.133,1.235,536945984,379.648,15.725,0.03655,-0.05603,345743000,216108496,236487008,0.097,0.77529997,0.42779,0.13393,USD,
7,100 Technology Center Drive,Suite 300,Stoughton,MA,02072,United States,781 713 3699,781 828 4697,https://www.collegiumpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",207,"{'maxAge': 1, 'name': 'Mr. Bart J. Dunn', 'title': 'Exec. VP of Strategy & Corp. Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,3,2,3,1693526400,1672444800,86400,2,23.19,23.22,22.5,23.27,23.19,23.22,22.5,23.27,0.0,0.832987,7.7303753,691509,691509,304824,312250,312250,22.65,22.69,800,800,805483840,15.4,30.22,1.5001208,22.9676,23.922,0.0,0.0,USD,1242365696,-0.02079,31140123,34734100,7404250,5937207,1690761600,1693440000,0.2132,0.0083,1.16119,20.04,0.258,5.784,3.915975,1672444800,1703980800,1688083200,-11161000,-0.32,2.93,36.98,2.314,5.409,NMS,EQUITY,COLL,COLL,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",1431005400,America/New_York,EDT,-14400000,22.65,37.0,30.0,34.0,34.5,1.8,buy,4,325470016,9.37,229700000,762353024,1.133,1.235,536945984,379.648,15.725,0.03655,-0.05603,345743000,216108496,236487008,0.097,0.77529997,0.42779,0.13393,USD,
8,100 Technology Center Drive,Suite 300,Stoughton,MA,02072,United States,781 713 3699,781 828 4697,https://www.collegiumpharma.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",207,"{'maxAge': 1, 'name': 'Mr. Scott  Sudduth', 'title': 'Head of Technical Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,3,2,3,1693526400,1672444800,86400,2,23.19,23.22,22.5,23.27,23.19,23.22,22.5,23.27,0.0,0.832987,7.7303753,691509,691509,304824,312250,312250,22.65,22.69,800,800,805483840,15.4,30.22,1.5001208,22.9676,23.922,0.0,0.0,USD,1242365696,-0.02079,31140123,34734100,7404250,5937207,1690761600,1693440000,0.2132,0.0083,1.16119,20.04,0.258,5.784,3.915975,1672444800,1703980800,1688083200,-11161000,-0.32,2.93,36.98,2.314,5.409,NMS,EQUITY,COLL,COLL,"Collegium Pharmaceutical, Inc.","Collegium Pharmaceutical, Inc.",1431005400,America/New_York,EDT,-14400000,22.65,37.0,30.0,34.0,34.5,1.8,buy,4,325470016,9.37,229700000,762353024,1.133,1.235,536945984,379.648,15.725,0.03655,-0.05603,345743000,216108496,236487008,0.097,0.77529997,0.42779,0.13393,USD,
